Senior Director, Clinical & Scientific Affairs; Director, Guideline Development at @AMPath. MBA, PhD, HCLD(ABB). Tweets are my own; RTs ≠ endorsements
Joined April 2014
- Tweets2.7K
- Following1K
- Followers867
- Likes4.2K
Robyn Temple-Smolkin retweeted
🔥 NGS isn’t underused due to lack of data. It’s underused because reports are HARD to use.
▫️@AMPath @Pathologists consensus: Only 1/17 NSCLC reports were oncologist-friendly.
▫️The fix: Standardized, guideline-aligned reporting.
🔗 sciencedirect.com/science/ar…
Robyn Temple-Smolkin retweeted
🚨 Big news: The U.S. District Court has ruled in our favor, thwarting the FDA’s attempt to impose excessive regulations on laboratory-developed testing procedures (LDTs). This is a win for labs, patients and innovation! Ruling and opinion: amp.org/advocacy/amp-v-fda/
Robyn Temple-Smolkin retweeted
Today's the last day to secure early-bird pricing on our live online Molecular Genetic Pathology Review Course in May! This course will include lectures, case studies, live Q&A sessions and in-depth discussions. Learn more and register: amp.org/events/molecular-gen…
Robyn Temple-Smolkin retweeted
We're at @TheUSCAP's annual meeting this weekend! Swing by booth 1004 to meet our membership manager, Jocelyn Friedrich; get your hands on some "Molecular in My Pocket" reference cards; and find out what being a member of @AMPath can mean for you. #USCAP2025
Robyn Temple-Smolkin retweeted
At our AMP Middle East meeting in Abu Dhabi, Somak Roy (@roysomak4)will give two presentations, one about what clinical bioinformaticians need to know and one about in silico resources for NGS bioinformatics pipeline validation.
See all speakers: ampmiddleeast25.amp.org/spea…
Robyn Temple-Smolkin retweeted
We're going to be at @TheUSCAP's annual meeting this weekend! Swing by booth 1004 to meet our membership manager, Jocelyn Friedrich; get your hands on some "Molecular in My Pocket" reference cards; and find out what being a member of @AMPath can mean for you. #USCAP2025
Robyn Temple-Smolkin retweeted
🔬 Dive into #bioinformatics challenges with our "Next-Generation Bioinformatics" certificate program! This online training examines complex genomic anomalies in NGS testing. 🌟 Members save 25%! Enroll ➡️ educate.amp.org/local/catalo…
ALT Graphic repeats what is in the post, but it also notes these topics are covered: highly homologous genes, molecular informatics at scale, structural variant discovery, structural variation detection, personalized genomics, and difficult-to-sequence genes and structural variants. It also says you get 6+ hours of lectures, slides, pre- and post-course tests and a certificate of completion from the Association for Molecular Pathology.
Robyn Temple-Smolkin retweeted
We convened a working group to update the guideline for classification, annotation, interpretation and reporting of somatic sequence variants published in 2017. The working group seeks comments on its draft recommendations. Read them and submit a comment: amp.org/clinical-practice/op…
Robyn Temple-Smolkin retweeted
NIST has developed a reference material to support the production of diagnostic tests for the bird flu (H5N1). This nonhazardous genetic material will enhance the nation’s response to outbreaks of disease and ensure companies’ quality control. Read more: nist.gov/news-events/news/20…
ALT A researcher wearing goggles and protective gloves works with a bottle and pipette
Robyn Temple-Smolkin retweeted
Free webinar on Jan. 30: "Germline Testing in Cancer Patients: Molecular Diagnostic Considerations
and Clinical Implications." It'll feature speaker Diana Mandelker of @MSKCancerCenter and provide continuing-education credit: educate.amp.org/local/catalo…
Robyn Temple-Smolkin retweeted
One of the top articles in 2024 in @JMDiagn, AMP's official journal:
⭐DPYD Genotyping Recommendations ⭐
jmdjournal.org/article/S1525…
#openaccess
Robyn Temple-Smolkin retweeted
Not sure what your lab should be doing in light of the FDA's final rule on laboratory-developed testing procedures? We've put together a webpage with a ton of resources to help you at each stage. Check it out and share it with others who need it: amp.org/advocacy/amp-v-fda/f…
Robyn Temple-Smolkin retweeted
.@AMPath is now a member organization of @AJCCancer, which "provides worldwide leadership in the development, promotion and maintenance of evidence-based systems for the classification and management of cancer." facs.org/quality-programs/ca… (cc: @AmColSurgCancer )
Robyn Temple-Smolkin retweeted
#LegacyContent: Recommendations for Cell-Free DNA Assay Validations: A Joint Consensus Recommendation of @AMPath and @Pathologists.
Free in the #OpenArchive: jmdjournal.org/article/S1525…
Robyn Temple-Smolkin retweeted
What a thrill it was last month to win both the American College of Medical informatics ACMI Morris F. Collen Award of Excellence (amia.org/communities/acmi-fe…) and the Association for Molecular Pathology @AMPath Award for Excellence in Molecular Diagnostics (amp.org/membership/awards-gr…)! While it was so great to see friends, my heart was particularly warmed by this video made by ACMI! vimeo.com/1031202534?share=c…
Robyn Temple-Smolkin retweeted
Resource alert: The AMP Clinical Practice Committee has assembled a list of available resources on H5N1 at amp.org/clinical-practice/re….
Please check back frequently for updates.
Image: flickr.com/photos/niaid/5377…
Robyn Temple-Smolkin retweeted
AMP Expo Chatter: Can AI Algorithms Be LDTs?
Conversations at the conference raised awareness of a growing issue in molecular pathology and diagnostics: the use of AI in lab-developed tests.
hubs.li/Q02Zhh2B0
Robyn Temple-Smolkin retweeted
Is #molecularpathology at risk? Laurie Menser shares details on the AMP lawsuit against the FDA’s FInal Rule 💬👇
ow.ly/iHvn50U7RUB
